Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408472 · ClinicalTrials.gov registry record · Phase 1
NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement
A Phase 1 study of Glaucoma, Primary Open Angle, sponsored by Jeffrey L Goldberg.
- Completed
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
- 1
- Study location
NCT01408472 is a Phase 1 study of Glaucoma, Primary Open Angle that has completed, run by Jeffrey L Goldberg. The registered enrollment target is 11 participants, below the 68-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01408472, a Phase 1 study of Glaucoma, Primary Open Angle, has completed, sponsored by Jeffrey L Goldberg.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
- 1
- Study location
Study Summary
Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple pre-clinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like glaucoma. We hypothesize that CNTF delivery to the human eye will provide neuroprotection (prevent loss of vision) and neuroenhancement (improve vision indices) in glaucoma. Patients in the trial will receive an NT-501 CNTF implant (made by Neurotech) into one eye, and will be carefully followed to evaluate safety and efficacy.
Conditions Studied
Interventions
- DRUG NT-501 CNTF Implant
Study Locations (1)
Florida
- Bascom Palmer Eye Institute, University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-04 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408472
The ClinicalTrials.gov registry entry for NCT01408472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 68-participant average among 5 other Glaucoma, Primary Open Angle trials with a reported enrollment target (84% lower). The listed sponsor is Jeffrey L Goldberg, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma, Primary Open Angle appearing as the primary indexed condition, and to 1 intervention - of which NT-501 CNTF Implant is the first listed.
NCT01408472 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01408472 about?
NCT01408472 is a clinical study titled "NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement". Ciliary Neurotrophic Factor (CNTF) has been demonstrated in multiple pre-clinical models to enhance survival and regeneration of retinal ganglion cells, the retinal neurons injured in diseases like glaucoma. We hypothesize that CNTF delivery to the human eye will provide neuroprotection (prevent los...
What is the current status of trial NCT01408472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2011-04. Estimated completion is 2014-10.
What conditions does trial NCT01408472 study?
This clinical trial studies the following conditions: Glaucoma, Primary Open Angle.
What interventions are being tested in trial NCT01408472?
The interventions under investigation include: NT-501 CNTF Implant (DRUG).
Who is sponsoring clinical trial NCT01408472?
This trial is sponsored by Jeffrey L Goldberg, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01408472 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma, Primary Open Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and IOP-Lowering Effects of WB007
COMPLETED · Phase 1
-
Adaptive Optics Retinal Imaging
RECRUITING · NA
-
Safety and Feasibility of the ELIOS System in POAG Patients
RECRUITING · NA
-
Caffeine Consumption in Glaucoma Patients and Healthy Subjects
RECRUITING · NA
-
Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.